News-content-element - European Biotechnology Magazine

ADVERTISEMENT

960x540

SPONSORED PUBLICATION

SLAS Journals Spotlight AI in Drug Discovery

As artificial intelligence reshapes life sciences research, two leading Elsevier Gold Open Access peer-reviewed journals, SLAS Discovery and SLAS Technology, invite contributions to Special Issues exploring how AI, automation and self-driving laboratories are transforming drug discovery. Submissions are accepted until 15 December 2026. more ➔

Ponchi Kantt-Neaz, Global Executive Business Director 3PBIOVIAN

SPONSORED PUBLICATION

3PBIOVIAN appoints Ponchi Kantt-Neaz as Global Executive Business Director

The appointment of Ponchi marking an important milestone in the company’s global commercial strategy and further strengthening its commercial leadership as the company continues to expand its presence in the global CDMO market. more ➔

Seite-62_BIO-Europe-2024-Event-Image

EBD Group/Informa

SPONSORED PUBLICATION

BIO-Europe 2026

Join us for the 2nd BIO-Europe in Cologne, Germany, November 9–11, 2026, the premier biopharma partnering event now transformed into a comprehensive forum for biotech leaders. more ➔

ELRIG was founded in 1999 as a network for laboratory researchers in the UK.

SPONSORED PUBLICATION

The connective matrix: ELRIG’s role in the drug discovery ecosystem

Drug discovery depends on more than breakthrough science alone. Progress increasingly emerges from connected ecosystems where academia, biotech, pharma, CROs and technology providers can openly exchange ideas, challenge assumptions and accelerate innovation together. more ➔

indivumed_beide_960x540-705x397

SPONSORED PUBLICATION

Indivumed, ready to set sail to the clinic

With the separation from the biobank service business, Hamburg-based Indivumed has repositioned itself as a therapeutics biotech. Its earlier work remains the core of its medical knowledge and the source of novel targets. To advance the already pre-validated selection more quickly, the company is now looking for partners. The response has been strong, say Matthias Evers and Hartmut Juhl in conversation … more ➔